Eltanexor
Cat.No:IE1000 Solarbio
CAS:1642300-52-4
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥98%
Appearance:White to off-white Solid
Qty:
Size:
{{cart_num}}
My Cart>
Small Molecule Compounds >
Inhibitors & Antagonists & Agonists >
Membrane Transporter & Ion Channel >
EltanexorCAS:1642300-52-4
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥98%
Appearance:White to off-white Solid
Qty:
Size:
CAS | 1642300-52-4 |
Name | Eltanexor |
Molecular Formula | C17H10F6N6O |
Molecular Weight | 428.29 |
Solubility | Soluble in DMSO ≥5mg/mL |
Purity | ≥98% |
Appearance | White to off-white Solid |
Storage | Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year |
MDL | MFCD30489739 |
SMILES | C1=C(C=C(C=C1C(F)(F)F)C(F)(F)F)C2=NN(C=N2)C=C(C3=CN=CN=C3)C(=O)N |
InChIKey | JFBAVWVBLRIWHM-AWNIVKPZSA-N |
InChI | InChI=1S/C17H10F6N6O/c18-16(19,20)11-1-9(2-12(3-11)17(21,22)23)15-27-8-29(28-15)6-13(14(24)30)10-4-25-7-26-5-10/h1-8H,(H2,24,30)/b13-6+ |
PubChem CID | 86345880 |
Target Point | CRM1 |
Passage | Membrane Transporter&Ion Channel |
Background | It is an oral bioactive inhibitor of XPO1 (exportin 1, CRM1), which inhibits XPO1-dependent nuclear output by directly targeting XPO1, showing strong anti-leukemia activity. |
Biological Activity | Eltanexor 是具有口服生物活性的XPO1 (CRM1)抑制剂。在AML细胞系,IC50范围为20-211 nM。[1-2] |
In Vitro | Eltanexor与selinexor表现出相似的体外药效,但eltanexor对中枢神经系统穿透力较低,因此耐受性更强,即使每日给药也是如此,而且与 selinexor 相比,eltanexor在 CLL 和 AML 小鼠模型中的存活率也有所提高。KPT-8602 的治疗窗口期更宽,还可以提高靶向疗效,从而与其他靶向抗癌疗法进行更有效的联合治疗。[2] |
In Vivo | 由于Eltanexor 的耐受性更好,因此Eltanexor可以每天给药,而且在急性髓细胞性白血病患者衍生的异种移植模型中,Eltanexor对白血病细胞和 LICs 都有更好的抗白血病疗效。重要的是,Eltanexor不会显著降低正常造血干细胞和祖细胞(HSPC)的频率,从而为消除导致复发的LIC提供了治疗窗口,同时保护了正常的HSPC。[1] |
Data Literature Source | [1]. Etchin J,et al. KPT-8602,a second-generation inhibitor of XPO1-mediated nuclear export,is well tolerated and highly active against AML blasts and leukemia-initiating cells. Leukemia. 2017 Jan;31(1): 143-150. [2]. Hing ZA,et al. Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies. Leukemia. 2016 Dec;30(12): 2364-2372. |
Unit | Bottle |
Specification | 1mg |
Remark:These protocols are for reference only. Solarbio does not independently validate these methods.
Note:
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.